Carl Zeiss Meditec Announces Agreement of Acquire D.O.R.C

Carl Zeiss Meditec AG announced today that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from its current owner Eurazeo SE, Paris, France. The acquisition will enhance and complement ZEISS Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors. It will also give the company access to one of the market’s most advanced dual-function systems – the EVA NEXUSTM platform. EVA NEXUSTM is the core of a strong portfolio, comprising of a dual-capable system and a full range of accessories, instruments and liquids offering a best-in-class solution across VR, cataract, and combined procedures, ensuring surgeons can rely on a single platform to cater to a variety of procedure types. “With the acquisition of Dutch Ophthalmic Research Center, we’ll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS’s position in the vitreo-retinal surgery segment and extend our leadership in the ophthalmic medical devices market,” says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG. “In the year when D.O.R.C. celebrates 40 years of surgeon-inspired innovation in ophthalmic surgery, we could not be more excited to join a market leader and visionary like ZEISS Medical Technology,” says Pierre Billardon, CEO of D.O.R.C. “We’ve built an amazing business with innovative, market-leading products and look forward to seizing this opportunity for growth and advancing the future of ophthalmic surgery. I am personally proud and immensely grateful to all of the team at D.O.R.C. for their commitment and expertise to help patients see again.” The transaction remains subject to applicable regulatory and antitrust approvals Source: https://dorcglobal.com/news/carl-zeiss-meditec-ag-announces-agreement-acquire-dorc